Related Experiment Videos
Efficacy and tolerability of peg-only laxative on faecal impaction and chronic constipation in children. A controlled
Francesco Savino1, Serena Viola, Maiullari Erasmo
1Department of Pediatrics 1, "Regina Margherita" Children's Hospital, University of Turin, Azienda Ospedaliera Città della Salute e della Scienza della Città di Torino, Turin, Italy. francesco.savino@unito.it
Insights
A new PEG-only laxative formulation demonstrated superior tolerability and acceptance compared to PEG-electrolyte (PEG-EL) in children with chronic constipation. The PEG-only option resulted in more frequent and regular bowel movements, improving treatment adherence.
Area of Science:
- Pediatric Gastroenterology
- Pharmacological Studies
- Gastrointestinal Motility Disorders
Background:
- Polyethylene glycol (PEG)-based laxatives are the standard treatment for pediatric constipation.
- Variations in inactive ingredients across PEG formulations can impact patient acceptance, compliance, and adherence.
- This study compares a novel PEG-only formulation against a reference PEG-electrolyte (PEG-EL) formulation.
Purpose of the Study:
- To evaluate and compare the efficacy, tolerability, acceptance, and compliance of a new PEG-only formulation versus a PEG-electrolyte (PEG-EL) formulation.
- To assess the effectiveness of both formulations in resolving fecal impaction and treating chronic constipation in children.
Main Methods:
- Randomized study involving children aged 2-16 years with chronic constipation (≥2 months).
- Treatment groups received either PEG-only (0.7 g/kg/day) or PEG-EL (1-4 sachets/day) for 4 weeks.
- A separate cohort received higher doses for fecal impaction resolution (PEG-only 1.5 g/kg/day or PEG-EL 4+ sachets/day).
Main Results:
- Both formulations achieved adequate constipation relief; however, PEG-only showed significantly higher weekly stool frequency (9.2 vs. 7.8, p=0.025) and more days with bowel movements (22.4 vs. 19.6, p=0.034).
- PEG-only demonstrated superior tolerability, with significantly lower rates of nausea and treatment-related difficulties (96% vs. 52%, p<0.001) and better taste acceptance (p<0.001).
- Fecal impaction resolved faster with PEG-only. Adverse events were minimal and comparable, though one PEG-EL patient discontinued due to abdominal pain.
Conclusions:
- The PEG-only formulation is better tolerated and accepted by children with chronic constipation compared to PEG-EL.
- Higher doses of PEG-only promote more frequent and regular soft stool passage than PEG-EL.
- The improved acceptance and tolerability of PEG-only formulations may enhance treatment adherence in pediatric populations.
Background:
PEG-based laxatives are considered today the gold standard for the treatment of constipation in children. PEG formulations differ in terms of composition of inactive ingredients which may have an impact on acceptance, compliance and adherence to treatment. We therefore compared the efficacy, tolerability, acceptance and compliance of a new PEG-only formulation compared to a reference PEG-electrolyte (PEG-EL) formulation in resolving faecal impaction and in the treatment of chronic constipation.
Methods:
Children aged 2-16 years with functional chronic constipation for at least 2 months were randomized to receive PEG-only 0.7 g/kg/day in 2 divided doses or 6.9 g PEG-EL 1-4 sachets according to age for 4 weeks. Children with faecal impaction were randomized to receive PEG-only 1.5/g/kg in 2 divided doses until resolution or for 6 days or PEG-EL with an initial dose of 4 sachets and increasing 2 sachets a day until resolution or for 7 days.
Results:
Ninety-six children were randomized into the study. Five patients withdrew consent before starting treatment. Three children discontinued treatment for refusal due to bad taste of the product (1 PEG-only, 2 PEG-EL); 1 (PEG-EL) for an adverse effect (abdominal pain). Intent-to-treat analysis was carried out in 49 children in the PEG-only group and 42 in the PEG-EL group.No significant differences were observed between the two treatment groups at baseline.Adequate relief of constipation in terms of normalized frequency and painless defecation of soft stools was achieved in all patients in both groups. The number of stools/week was 9.2 ± 3.2 (mean ± SD) in the PEG-only group and 7.8 ± 2.4 in the PEG-EL group (p = 0.025); the number of days with stool was 22.4 ± 5.1 in the PEG-only group and 19.6 ± 7.2 in the PEG-EL group (p = 0.034).In the PEG-only group faecaloma resolution was observed in 5 children on the second day and in 2 children on the third day, while in the PEG-EL group it was observed in 2 children on the second day, in 3 children on the third day and in 1 child on the fifth day.Only 2 patients reported mild treatment-related adverse events: 1 child in the PEG-only group had diarrhoea and vomiting and 1 child in the PEG-EL group had abdominal pain requiring treatment discontinuation. The PEG-only preparation was better tolerated as shown by the lower frequency of nausea than in the PEG-EL group.In the PEG-only group, 96% of patients did not demonstrate any difficulties associated with treatment, as compared with 52% of patients in the PEG-EL group (p < 0.001). Also, the PEG-only formulation taste was better than that of PEG-EL (p < 0.001). The difference between the percentage of subjects who took > 80% of the prescribed dose was in favour of the PEG-only group (98% vs. 88%), though it did not reach a conventional statistical level (p = 0.062).
Conclusion:
PEG-only was better tolerated and accepted than PEG-EL in children with chronic constipation. At the higher PEG doses recommended by the manufactures children in the PEG-only group had higher and more regular soft stool frequency than PEG-EL.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...